Evidence map›Paper›PMID 42399256›Full record

ArticleNPJ Parkinson's disease2026

Sternum-worn vibrotactile device in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot trial.

Viktoria Azoidou, Essa Bhadra, Ellen Camboe, Kamalesh C Dey, Alexandra Zirra, Kira Rowsell, Corrine Quah, Caroline Budu, Thomas Boyle, David Gallagher and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06174948 (The Use of the CUE1/CUE1+ Device in People With Idiopathic Parkinson's Disease and Related Disorders), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06174948 narecruitingnot on this map

The Use of the CUE1/CUE1+ Device in People With Idiopathic Parkinson's Disease and Related Disorders: A Feasibility Study

TypeinterventionalSponsorQueen Mary University of LondonRan2024 to 2025Enrolled70ConditionsParkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Different Types of Tremor Including Essential Tremor, DystoniaArmsCUE1 non-invasive device, CUE1+ device active vs sham CUE1+ device
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Viktoria AzoidouCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Essa BhadraDepartment of Neurology, Royal London Hospital, Barts Health, London, UK.
Ellen CamboeCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Kamalesh C DeyCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Alexandra ZirraCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Kira RowsellNeurology Department, Homerton Healthcare NHS Foundation Trust, London, UK.
Corrine QuahNeurology Department, Homerton Healthcare NHS Foundation Trust, London, UK.
Caroline BuduDepartment of Neurology, Royal London Hospital, Barts Health, London, UK.
Thomas BoyleOlder Person's Services & GIM Special Interest in Parkinson's Disease, Royal London Hospital, London, UK.
David GallagherDepartment of Neurology, Royal London Hospital, Barts Health, London, UK.
Jonathan P BestwickCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Alastair J Noyce *Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Cristina Simonet *Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK. c.simonet@qmul.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective, non-invasive treatments for motor and non-motor symptoms in Parkinson's disease (PD) remain limited, and wearable vibrotactile stimulation may help by enhancing sensorimotor integration. This multi-centre, double-blind, pilot randomised controlled trial evaluated the usability, safety and tolerability of the CUE1+ sternum-worn vibrotactile device, with exploratory clinical outcomes compared with a sham device. Fifty adults with idiopathic PD, stable on antiparkinsonian medication, were randomised to active CUE1+ (n = 25) or sham (n = 25) for 12-weeks (8 h/day), with ON-medication assessments at baseline and week-13. Four participants (8%) discontinued; compliance exceeded 95% in both groups, and 2 (4.2%) experienced mild, transient skin irritation. Exploratory between-group differences favoured active stimulation on MDS-UPDRS Part III (-11.1 points; 95%CI -17.3 to -4.9) and the PDQ-39 Summary Index (-7.6 points; 95%CI -12.3 to -3.0). CUE1+ was usable, safe, and well tolerated. The exploratory clinical signals do not establish efficacy and require confirmation in adequately powered trials using an active vibrotactile sham. Trial registration: ClinicalTrials.gov, NCT06174948. Registered 13 February 2024.

Identifiers

PMID42399256
PMCPMC13612825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.